about
Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb ActivationHIV-1 expression within resting CD4+ T cells after multiple doses of vorinostatRapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assayA novel cell-based high-throughput screen for inhibitors of HIV-1 gene expression and budding identifies the cardiac glycosides.Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance.Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations.Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.The mTOR Complex Controls HIV Latency.Measuring the latent reservoir in vivo.Modeling HIV-1 Latency in Primary T Cells Using a Replication-Competent Virus.Replication of Human Herpesviruses Is Associated with Higher HIV DNA Levels during Antiretroviral Therapy Started at Early Phases of HIV Infection.The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb.Defective HIV-1 proviruses produce novel protein-coding RNA species in HIV-infected patients on combination antiretroviral therapy.CD8+ T cells from HLA-B*57 elite suppressors effectively suppress replication of HIV-1 escape mutants.New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo.Specific and Stable Suppression of HIV Provirus Expression In Vitro by Chimeric Zinc Finger DNA Methyltransferase 1.Quantification of plasma HIV RNA using chemically engineered peptide nucleic acids.IFITM1 targets HIV-1 latently infected cells for antibody-dependent cytolysis.Standard vaccines increase HIV-1 transcription during antiretroviral therapy.Current views on HIV-1 latency, persistence, and cure.Defective HIV-1 Proviruses Are Expressed and Can Be Recognized by Cytotoxic T Lymphocytes, which Shape the Proviral Landscape.Reactivation of HIV-1 from Latency by an Ingenol Derivative from Euphorbia Kansui.Quantification of Total and 2-LTR (Long terminal repeat) HIV DNA, HIV RNA and Herpesvirus DNA in PBMCs.Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy.Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles.The bromodomain and extraterminal domain inhibitor bromosporine synergistically reactivates latent HIV-1 in latently infected cells.BET inhibitors RVX-208 and PFI-1 reactivate HIV-1 from latency.Class 1-selective histone deacetylase inhibitors enhance HIV latency reversal while preserving the activity of HDAC isoforms necessary for maximal HIV gene expression.What do we measure when we measure cell-associated HIV RNA.Inducible HIV RNA transcription assays to measure HIV persistence: pros and cons of a compromise.HIV latency is reversed by ACSS2-driven histone crotonylation.Physical lysis only (PLO) methods suitable as rapid sample pretreatment for qPCR assay.
P2860
Q28546901-8E60BA11-880A-414B-96C4-A0C2C6049AB6Q34106191-FDE07059-49F5-44BA-B905-35BA693F20C8Q34758220-E247766A-69D2-4BA7-9D7E-53FBB0B36C82Q35052661-8DDDD114-BD5A-4E5F-9B59-568CD52E0104Q35237575-0F778370-7D04-4F8A-9CA6-33B1BCA25977Q35720063-7D97F4D8-17CB-48F4-A619-1654E99650A0Q36076018-6F60E34C-DE13-420D-BFA7-F0B6835C806FQ36225471-9B1D5DC5-A5D2-4526-B507-136278AA2312Q36515110-108B4D55-3611-4759-9B9C-9EDD0A5E546CQ36602033-D98894F7-38A7-4BD7-B04D-3EAB149AFC92Q36736353-7C10E36C-2D26-4EF2-A230-CBDE4EF7B165Q36790027-5F9C2908-17CD-4A60-8815-2FB8DA9198D7Q37161557-3E240A64-8F10-4053-A51F-C3D8ED1BDC10Q37427587-C3C423A8-C9EF-45EE-8035-960EC818BB4EQ37695001-48EA5FAD-8B55-4F88-95F6-3B34F5122521Q37718212-9CBDC2C5-1395-458C-B440-AF747D9C3651Q38303708-C83AD298-5324-49BC-A8BD-8E1B79D4303DQ38720858-5336A72E-FFE2-4BDB-B552-9A3813E0B2B1Q38840779-473C2520-3713-4028-9D57-3EA4A3053929Q38973362-63F9FC55-132A-4207-B990-EFE9B6375536Q39362365-7FD48197-CD42-40C8-A9DF-72EDDD28EC6BQ40069803-980C3834-1DDB-407D-ACD5-EBDB1002F994Q40394431-3082B8E9-4DCE-45BB-87B8-9386FCDE55CFQ40523184-8AFAECAA-6FCC-4166-8537-5ED4A0EEE194Q40527984-039A4DF2-3F80-4867-B8F6-BB522CD86161Q47098415-E4CECF73-2F19-40EE-9411-BD9CCE267504Q47120827-218B5B77-25C6-4751-804A-0A7B4A5D99A9Q47234362-28087D3C-AFC5-4161-8BE6-999DEF091DE1Q47548192-2647D7E8-854B-4320-9713-C9147024A2BCQ47552344-A453B64E-72F7-40B9-80CF-C1BEECE3E407Q49851068-8F14BAF7-E74D-4CAE-9A52-726A9BEC1592Q54191859-5C536FD2-F2D1-443E-AC2E-4330B55A17EA
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
A novel PCR assay for quantification of HIV-1 RNA.
@en
type
label
A novel PCR assay for quantification of HIV-1 RNA.
@en
prefLabel
A novel PCR assay for quantification of HIV-1 RNA.
@en
P2093
P2860
P356
P1433
P1476
A novel PCR assay for quantification of HIV-1 RNA.
@en
P2093
Evelyn E Eisele
Gregory M Laird
Liang Shan
S Alireza Rabi
P2860
P304
P356
10.1128/JVI.00006-13
P407
P577
2013-03-27T00:00:00Z